Treatment of familial erythromelalgia with venlafaxine

Firmin, David; Am, Roguedas; Greco, M; Morvan, Chu; Legoupil, Délphine; Fleuret, C.; Miséry, Laurent

doi:10.1111/j.1468-3083.2006.02039.x

Cited by 14 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, preliminary results in PE indicate low or absent effectivity of this drug (62). Moreover, in those cases in which lidocaine or mexiletine are helpful in PE, the efficacy of these agents is only partial or transient (63).…”

Section: Implications For New Therapeutic Approaches To Painmentioning

confidence: 77%

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

Drenth¹,

Waxman²

2007

J. Clin. Invest.

309

269

View full text Add to dashboard Cite

Section: Implications For New Therapeutic Approaches To Painmentioning

confidence: 77%

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

Drenth¹,

Waxman²

2007

J. Clin. Invest.

309

269

View full text Add to dashboard Cite

“…1,89 Sixty percent of children with SCN9A-positive IEM identified by systematic review, and 3 of 4 cases at our center, had significant peripheral tissue injury secondary to prolonged cold immersion or rubbing/scratching. Prolonged ice immersion and/or environmental cooling have been associated with severe hypothermia requiring intensive care; 40,70,74,75,79 skin injury with sepsis and significant morbidity; 3,31,48,90,91 and mortality. 49,55,61,90 The extent to which hypertension 50 and increased plasma or urine catecholamines 44,92 in pediatric IEM cases are secondary to uncontrolled pain and stress is difficult to determine.…”

Section: Discussionmentioning

confidence: 99%

“…2,6,16,33,50,56,[59][60][61][62][63][64][65][66][67][68] SCN9A-related IEM cases in adults reporting onset of symptoms before 18 years are also listed (Table 2B; online). 2,3,6,17,18,33,48,61,63,[69][70][71][72][73][74][75][76][77][78][79][80][81][82] Overall, pediatric onset IEM was associated with 24 different Na v 1.7 channel substitutions. As in the systematic review, additional cases reported major complications associated with excessive cooling or ice immersion: skin injury and sepsis resulting in amputations (p.L858F) 78 and mortality (p.F216S); 61,70 and severe hypothermia (p.L858F 78 ) with associated cerebral symptoms (p.I848T, 75 p.F216S 70 ) (Table 2B; online).…”

Section: Descriptive Synthesis Of Systematic Literature Reviewmentioning

confidence: 99%

Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series

Keen

Verriotis

et al. 2019

The Journal of Pediatrics

View full text Add to dashboard Cite

Objectives. To evaluate the clinical features of erythromelalgia in childhood associated with gainof-function SCN9A mutations that increase activity of the Na v 1.7 voltage-gated sodium channel we: i) conducted a systematic review of pediatric presentations of erythromelalgia related to SCN9A mutations; and ii) compared pediatric clinical presentations of symptomatic erythromelalgia, with or without SCN9A mutations. Study Design PubMed, Embase, and PsycINFO Databases were searched for reports of IEM in childhood. Clinical features, management and genotype were extracted. Case notes of pediatric patients with erythromelalgia from the Great Ormond Street Hospital (GOSH) Pain Service were reviewed for clinical features, patient-reported outcomes and treatments. Children aged over 10 years were recruited for quantitative sensory testing (QST). Results Twenty-eight publications described erythromelalgia associated with 15 different SCN9A gene variants in 25 children. Pain was severe and often refractory to multiple treatments, including non-specific sodium channel blockers. Skin damage or other complications of cold immersion for symptomatic relief were common (60%). SCN9A mutations resulting in greater hyperpolarizing shifts in Na v 1.7 sodium channels correlated with symptom onset at younger ages (P=.016). Variability in reporting and potential publication bias towards severe cases limit any estimations of overall incidence. At GOSH, reported symptoms in both groups were similar but co-morbidities were more common in SCN9A-positive cases. QST revealed marked dynamic warm allodynia. Conclusions: IEM in children is associated with difficult-to-manage pain and significant morbidity. Standardized reporting of outcome and management in larger series will strengthen

show abstract

“…Selective serotonin and norepinephrine reuptake inhibitors such as fluoxetine, sertraline, and venlafaxine have also been used with reported remission 53,54. Serotonin antagonists such as methysergide and pizotifen have been tried with some reported effectiveness 110,111.…”

Section: Pharmacotherapymentioning

confidence: 99%

Current pain management strategies for patients with erythromelalgia: a critical review

Tham¹,

Giles²

2018

JPR

View full text Add to dashboard Cite

Erythromelalgia (EM) is a rare disorder characterized by erythematous, warm, painful extremities, which is often precipitated by cold conditions. The pathophysiology of EM is incompletely understood. Recent investigations have identified sodium channelopathy as a genetic cause for this pain condition, classified as primary inherited EM. Other subtypes are idiopathic EM and secondary EM. The management of pain in EM is challenging as no single therapy has been found to be effective. There is varying response to pharmacotherapy and significant variability within this clinical population, resulting in a stepwise trial and error approach. Consequently, EM is often associated with poorer health-related quality of life with higher morbidity. There is currently no consensus or guidelines on management of pain in EM. This is a review of the literature on management of pain using pharmacologic, procedural intervention and nonpharmacologic treatment in children and adults with EM.

show abstract

Treatment of familial erythromelalgia with venlafaxine

Cited by 14 publications

References 8 publications

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series

Current pain management strategies for patients with erythromelalgia: a critical review

Contact Info

Product

Resources

About